DK1107996T3 - Humane anti-faktor IX/IXa-antistoffer - Google Patents

Humane anti-faktor IX/IXa-antistoffer

Info

Publication number
DK1107996T3
DK1107996T3 DK99943928T DK99943928T DK1107996T3 DK 1107996 T3 DK1107996 T3 DK 1107996T3 DK 99943928 T DK99943928 T DK 99943928T DK 99943928 T DK99943928 T DK 99943928T DK 1107996 T3 DK1107996 T3 DK 1107996T3
Authority
DK
Denmark
Prior art keywords
factor
ixa
fix
human anti
inhibiting
Prior art date
Application number
DK99943928T
Other languages
English (en)
Inventor
Camellia W Adams
Brigitte Devaux
Dan L Eaton
Philip E Hass
J Kevin Judice
Daniel Kirchhofer
Shelley Suggett
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1107996T3 publication Critical patent/DK1107996T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK99943928T 1998-08-28 1999-08-26 Humane anti-faktor IX/IXa-antistoffer DK1107996T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9823398P 1998-08-28 1998-08-28
US12276799P 1999-03-03 1999-03-03
PCT/US1999/019453 WO2000012562A1 (en) 1998-08-28 1999-08-26 HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Publications (1)

Publication Number Publication Date
DK1107996T3 true DK1107996T3 (da) 2002-09-16

Family

ID=26794469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99943928T DK1107996T3 (da) 1998-08-28 1999-08-26 Humane anti-faktor IX/IXa-antistoffer

Country Status (15)

Country Link
US (3) US6624295B1 (da)
EP (1) EP1107996B1 (da)
JP (1) JP4638035B2 (da)
CN (1) CN1183160C (da)
AT (1) ATE217889T1 (da)
AU (1) AU766551C (da)
BR (1) BR9913435A (da)
CA (1) CA2341276C (da)
DE (1) DE69901569T2 (da)
DK (1) DK1107996T3 (da)
ES (1) ES2177316T3 (da)
IL (1) IL140917A0 (da)
NZ (1) NZ509430A (da)
PT (1) PT1107996E (da)
WO (1) WO2000012562A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
CN100339132C (zh) * 2000-05-15 2007-09-26 史密丝克莱恩比彻姆公司 抗血栓剂
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1905839B2 (de) * 2006-09-22 2019-07-10 Wacker Chemie AG Verfahren zur fermentativen Herstellung von Proteinen
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2011121020A1 (en) * 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
RU2015149979A (ru) 2010-03-30 2019-01-15 Октафарма Аг Способ очистки белка фактора роста
US20130079280A1 (en) * 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP2717054B1 (en) * 2011-05-23 2018-11-28 Sekisui Medical Co., Ltd. Method for inhibiting non-specific reaction in pivka-ii measurement reagent
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
CA3051639A1 (en) 2017-02-01 2018-08-09 Novo Nordisk A/S Procoagulant antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720983A1 (de) * 1987-06-25 1989-01-05 Hoechst Ag Immunometrisches bestimmungsverfahren
WO1991016353A1 (en) 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
UA41929C2 (uk) 1994-03-17 2001-10-15 Мерк Патент Гмбх Анти-ефрр одноланцюжковий fv,молекула днк,яка його кодує, анти-ефрр антитіло,спосіб одержання анти-ефрр одноланцюжкового fv,спосіб одержання повного анти-ефрр антитіла та фармацевтична композиція (варіанти)
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
PT1107996E (pt) 2002-10-31
EP1107996A1 (en) 2001-06-20
ES2177316T3 (es) 2002-12-01
AU766551B2 (en) 2003-10-16
CN1183160C (zh) 2005-01-05
CA2341276C (en) 2005-10-11
US7354585B2 (en) 2008-04-08
JP4638035B2 (ja) 2011-02-23
ATE217889T1 (de) 2002-06-15
BR9913435A (pt) 2001-09-25
AU5692399A (en) 2000-03-21
CN1317015A (zh) 2001-10-10
DE69901569T2 (de) 2002-12-19
US20060193851A1 (en) 2006-08-31
US20060088534A1 (en) 2006-04-27
CA2341276A1 (en) 2000-03-09
DE69901569D1 (de) 2002-06-27
US6624295B1 (en) 2003-09-23
US7049411B2 (en) 2006-05-23
JP2002523081A (ja) 2002-07-30
IL140917A0 (en) 2002-02-10
WO2000012562A1 (en) 2000-03-09
EP1107996B1 (en) 2002-05-22
NZ509430A (en) 2002-04-26
AU766551C (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
MEP8209A (en) Modified factor viii
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
TR200001954T2 (tr) Faktör XA'nın önleyicileri olarak indol türevleri.
DE50010115D1 (de) Zusammensetzung und verfahren zur entkeimung von luft
DK0842934T3 (da) 5-HT1F agonister
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
BR9911785A (pt) Combinações de farnesil transferase de proteìna e inibidores de redutase de hmg coa e seu uso para tratar câncer
TR200200278T2 (tr) Kalsilitik bileşimler